Furthermore, we also explored the association of tumor CCT6A expression with clinicopathological features and observed that tumor CCT6A high expression was correlated with LYN metastasis, raised TNM stage, and abnormal CEA in NSCLC patients. This evidence concerns the gene CEACAM5 and neoplasm.